Frontierby eninvs

Language: EN / RU

← Region

Ozon Pharm (OZPH) RUB

Ozon Pharmaceutical is Russia's largest generic drug maker by volume, producing a wide portfolio of low-cost medicines in Samara region and developing biotech products through Mabscale.

At a glance: strengths & risks
✓Revenue growing (+12% y/y, H1 2026)✓Profit growing (+90% y/y, H1 2026)✓Margins improving (34%→37%, H1 2026)✓Low leverage (0.8x EBITDA)

Sector: Healthcare

RU_OZPH

Price chart

46.68 RUBDay -1.64%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
46.68 RUB · -1.64%
Market cap
54.5 bn RUB

Growth

Δ revenue y/y
23.6%
Δ EBITDA y/y
32.1%

Multiples

P/E (LTM)
9.5x
3y avg: 10.1x
P/B (FY)
1.6x
P/E (ann.)
8.4x
EV/EBITDA (LTM)
5.3x
3y avg: 6.1x
EV/EBITDA (ann.)
5.5x

Cash return

Dividend yield
2.8%
FCF yield (LTM)
-2.0%

Liquidity

Daily turnover (MOEX)
52.3 mln RUB

Shares: connector/market_inputs

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in B RUB, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB RUBOperating profitB RUBD&AB RUBEBITDAB RUBNet profitB RUBOperating CFB RUBCapex + M&AB RUBAssetsB RUBEquityB RUBROE (annualized)Net debtB RUBSource
2026-06-30Q2 2026 (3M)OK14.8
y/y —
4.9
y/y —
0.6
y/y —
5.5
y/y —
3.2
y/y —
6.8-2.352.3
y/y —
36.0
y/y —
18.8%5.4Report (PDF)
2025-12-31Q4 2025 (3M)OK10.2
y/y 15.4%
4.0
y/y 16.8%
0.3
y/y 6.8%
4.3
y/y 16.0%
2.7
y/y 17.9%
-0.1-1.253.2
y/y 7.5%
33.2
y/y 31.0%
19.3%9.2Report (PDF)
2025-09-30Q3 2025 (3M)OK8.2
y/y 52.7%
2.9
y/y 138.3%
0.3
y/y 0.0%
3.2
y/y 110.0%
1.7
y/y 356.3%
0.5-1.051.3
y/y 25.8%
30.7
y/y 33.7%
7.7%8.3Report (PDF)
2025-06-30Q2 2025 (3M)OK6.4
y/y -4.2%
1.7
y/y -15.1%
0.3
y/y 19.8%
2.1
y/y -11.1%
0.7
y/y -37.2%
2.3-1.050.3
y/y 31.0%
29.1
y/y 30.0%
10.4%10.0Report (PDF)
2025-03-31Q1 2025 (3M)OK6.9
y/y 45.2%
2.2
y/y 70.0%
0.3
y/y 0.0%
2.5
y/y 58.4%
1.0
y/y 28.0%
0.4-0.749.6
y/y —
26.3
y/y —
15.4%8.7Report (PDF)
2024-12-31Q4 2024 (3M)OK8.8
y/y 46.7%
3.4
y/y 137.0%
0.3
y/y -68.6%
3.7
y/y 56.6%
2.3
y/y 164.8%
-0.4-1.549.5
y/y 45.2%
25.3
y/y 48.0%
19.1%10.1Report (PDF)
2024-09-30Q3 2024 (3M)OK5.3
y/y -8.5%
1.2
y/y -53.1%
0.3
y/y 1404.3%
1.5
y/y -41.5%
0.4
y/y -80.4%
-0.8-1.340.8
y/y —
22.9
y/y —
2.2%18.5Report (PDF)
2024-06-30Q2 2024 (3M)OK6.7
y/y 73.1%
2.0
y/y 186.5%
0.3
y/y 19.4%
2.3
y/y 146.6%
1.1
y/y 253.1%
4.7-0.738.4
y/y —
22.4
y/y —
—8.0Report (PDF)
2024-03-31Q1 2024 (3M)PARTIAL4.7
y/y —
1.3
y/y —
0.3
y/y —
1.6
y/y —
0.8
y/y —
2.3-0.7—
y/y —
—
y/y —
—10.0Report (PDF)
2023-12-31Q4 2023 (3M)OK6.0
y/y —
1.4
y/y —
0.9
y/y —
2.3
y/y —
0.9
y/y —
-2.4-0.234.1
y/y —
17.1
y/y —
—8.7Report (PDF)
2023-09-30Q3 2023 (3M)PARTIAL5.8
y/y —
2.6
y/y —
0.0
y/y —
2.6
y/y —
1.9
y/y —
1.6-0.3—
y/y —
—
y/y —
—9.1Report (PDF)
2023-06-30Q2 2023 (3M)PARTIAL3.9
y/y —
0.7
y/y —
0.2
y/y —
0.9
y/y —
0.3
y/y —
2.1-0.1—
y/y —
—
y/y —
—9.5Evidence

Net debt structure (leases included, IFRS 16) 2026-06-30

Short-term debt (incl. ST leases)1 450
Long-term debt (incl. LT leases)6 626
− Cash & equivalents2 727
Net debt5 350

Net debt / LTM EBITDA: 0.4x

Revenue & EBITDA

RevenueEBITDA

Quarterly values (₽ mln)

05 00010 00015 0002023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 H1

Year-over-year change

-50%0%50%100%150%2023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 H1

Cash flow

Operating and investing cash flow (OCF + ICF) (₽ mln)

-4 000-2 00002 0004 0006 0002023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 H1

Net debt / cash (₽ mln)

05 00010 00015 00020 0002023 q42024 q12024 q22024 q32024 q42025 q12025 q22025 q32025 q42026 H1

Profit and cash

Worth a look
In a typical year of 2022–2025 operating cash flow came to 0.84x of reported net profit; after capex, 0.11x.
year2022202320242025
cash flow / profit0.03x1.16x1.26x0.53x
accruals, % of assets—-1.9%-2.5%5.5%
Last twelve months (to 2025-Q1): 0.53x of profit came back as operating cash flow.
net debt / EBITDA 0.8x · EBIT covers interest 3.2x · capex 2.4x of depreciation
● In a typical year operating cash flow covered 85% of reported profit (4 profitable years).
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Research & reviews

Our earnings breakdowns and investment notes on this issuer.

All research →

Category demand: Лекарства и медицинские товары (SberIndex) — backdrop

The “Лекарства и медицинские товары” category is weekly consumer pharmacy spending (% YoY), i.e. retail demand. For a manufacturer like Ozon Pharmaceutica this is only a demand backdrop, not a revenue proxy — sales depend on product mix, launches and B2B/government channels — so no spread to revenue is shown.

Лекарства и медицинские товары latest week (2026-10-17): +10.2% YoY · flat3-wk smooth: +9.7% vs 8-wk avg +9.5% (+0.2 pp)All categories: +7.2%

-5%+4%+12%+21%+30%Q4'24+8%Q1'25+16%Q2'25+14%Q3'25+10%Q4'25+9%Q1'26+5%Q2'26+9%Q3'26+10%Q4'26+10%+10.2%weekly % YoYquarter average

Average growth by quarter, % YoY: * квартал ещё не закончен

3кв 2025
+9.7%
4кв 2025
+8.7%
1кв 2026
+4.9%
2кв 2026
+8.8%
3кв 2026
+10.0%
4кв 2026 *
+9.7%

Source: SberIndex, updated 2026-10-22.

Government orders: 44-FZ contracts

Last 12 months (2025-05 – 2026-10): 36 459 contracts worth RUB 26 035 mn -32% YoY.

05 0002024-05: 3061 contracts 3 058 RUB mn2024052024-06: 2597 contracts 2 189 RUB mn062024-07: 2667 contracts 2 197 RUB mn072024-08: 2169 contracts 1 226 RUB mn082024-09: 2454 contracts 3 711 RUB mn092024-10: 2822 contracts 2 629 RUB mn102024-11: 4648 contracts 3 216 RUB mn112024-12: 4741 contracts 4 277 RUB mn122025-01: 4385 contracts 3 454 RUB mn2025012025-02: 2846 contracts 3 736 RUB mn022025-03: 4263 contracts 6 050 RUB mn032025-04: 4270 contracts 2 678 RUB mn042025-05: 3366 contracts 1 762 RUB mn052025-06: 3300 contracts 1 506 RUB mn062025-07: 2363 contracts 1 655 RUB mn072025-08: 2441 contracts 1 941 RUB mn082025-09: 3066 contracts 1 840 RUB mn092025-10: 3855 contracts 2 815 RUB mn102025-11: 4336 contracts 3 331 RUB mn112026-06: 3855 contracts 2 776 RUB mn062026-07: 2694 contracts 1 925 RUB mn072026-08: 2474 contracts 1 982 RUB mn082026-09: 3182 contracts 2 821 RUB mn092026-10: 1527 contracts 1 681 RUB mn10

own items, estimate   full contract value

Half-yearContractsValue, mnOwn items, mnRevenue, mnShareYoY
2023H116 87912 8274 6607 73060%–
2023H211 0726 7533 59111 99530%–
2024H120 71622 7636 61911 41458%+77%
2024H219 50117 2567 56714 14853%+156%
2025H122 43019 1858 59813 26465%-16%
2025H216 06111 5835 43418 32430%-33%
2026H13 8552 7761 22114 8218%-86%
2026H2 *9 8778 4093 815–––

Largest customers, 12 months

Source: EIS contract registry (zakupki.gov.ru), 44-FZ, by contract signing date; 223-FZ hides suppliers and is excluded. Contract value is the customer price incl. VAT and distributor margin, not the producer's revenue, and leads shipments. Manufacturer - OOO Ozon and Ozon Pharm. Own-item share of contract value across 966 parsed cards: 56%. Data through 2026-10. * - incomplete half-year.

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth +24% vs +30% the year before — a -6.0 pp move. 3-year CAGR +19%.
revenue growth by year: 2023 +4% · 2024 +30% · 2025 +24%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

EV/EBITDA — daily history

Current 5.3x · 3-year 75th pct 6.7x

EV/EBITDA3-year 75th pct

Peer comparison

Group: Healthcare. Each peer is shown as it trades and re-priced onto this company's market (Russia) by the ratio of our coverage medians.

CompanyMarketCap, $bnEV/EBITDAEV/EBITDA, adjusted
UNITEDHEALTH GROUP INCUS377.715.4x2.7x
Merck & Co., Inc.US375.715.7x2.8x
AMGEN INCUS237.617.5x3.1x
NetcareSouth Africa1.24.9x3.6x
Life HealthcareSouth Africa1.15.7x4.2x
AbbVie Inc.US505.024.4x4.3x
JOHNSON & JOHNSONUS620.724.7x4.4x
THERMO FISHER SCIENTIFIC INC.US261.127.0x4.8x
ELI LILLY & CoUS1137.133.1x5.9x
PromomedRussia1.16.4x6.4x
Mitra Keluarga KaryasehatIndonesia1.19.0x6.5x
MD MedicalRussia1.27.1x7.1x
Group median15.5x4.3x
Group average15.9x4.6x
This companyRussia0.75.3x5.3x

Group median 15.5x as traded, 4.3x adjusted; this company 5.3x — a 21% premium.

Group average 15.9x as traded, 4.6x adjusted; against the average this company is at a 13% premium.

At the adjusted group median the market cap would be -20% versus today.

The gap and the implied upside are measured against the median: one richly priced peer moves an average, not a median. The market adjustment uses our coverage medians (US 20.9x, Russia 3.7x, South Africa 5.0x, Kazakhstan 4.7x, India 18.8x, Indonesia 5.1x); it is about where a name is listed, not what it does. Peer multiples come from the nightly rebuild of 2026-10-22; the company's own is live.

Dividend potential

Dividend-model upside: -60%

The payout is forecast from smoothed profit × payout ratio, capped by free cash flow (developers exempt — escrow) and floored at the recent actual dividend (companies hold payouts while profitable). Fair yield = key rate + the historical yield-spread to the rate (so growers that historically traded below the rate score higher). Upside = fair price / current − 1.

1 · Forecast dividend (per policy)
Smoothed net profit (median YTD-ann./LTM/FY)6 bn RUB
Payout ratio19%
Free cash flow (FY, OCF − capex) — not a cap (leverage 0.8x)-1 bn RUB
Recent actual dividend (3-yr median)1.30 ₽
= Forecast dividend per share1.30 ₽
2 · Fair yield (spread to key rate)
CBR key rate14.0%
Historical yield spread to rate (3-yr median)-14.5 pp
= Fair dividend yield7.0%
3 · Valuation → upside
Current price47.14 ₽
Forecast dividend yield2.8%
Fair price (dividend-based)18.84 ₽

Forecast, not investment advice. Earnings annualization and policy assumptions are estimates.

Three-year model and IRR with caveats

Expected IRR: +15% (bear -8% … bull +40%)

price in 3 years 66.00 ₽ (+40% к 47.00 ₽); dividends along the way 5.28 ₽ (+11% цены); base — LTM на 2026-06-30 (H1)

Metric, RUB mlnLTM, actual
12m to 30.06.2026
2027
12m to 30.06
2028
12m to 30.06
2029
12m to 30.06
Revenue33.1 bn38.6 bn43.3 bn47.3 bn
Revenue growth—+17%+12%+9%
EBITDA12.9 bn14.9 bn16.6 bn18.0 bn
EBITDA margin39.0%38.6%38.3%37.9%
less D&A1.2 bn1.3 bn1.4 bn1.5 bn
EBIT11.7 bn13.6 bn15.1 bn16.4 bn
less net interest1.7 bn884759727
less tax2.3 bn3.2 bn3.6 bn3.9 bn
Net profit7.7 bn9.5 bn10.8 bn11.8 bn
Capex4.3 bn4.5 bn5.0 bn5.5 bn
Capex to revenue13.0%11.6%11.6%11.6%
Free cash flow4.6 bn2.9 bn3.2 bn3.5 bn
Net debt5.4 bn5.8 bn6.2 bn6.7 bn
Net debt / EBITDA0.4x0.4x0.4x0.4x
Dividend per share1.30 ₽1.57 ₽1.77 ₽1.94 ₽
Yield on current price2.8%3.3%3.8%4.1%
Where the growth comes from
Revenue-growth sourceweightgrowth: yr 1 · 2 · 3
Realised pace (acceleration/deceleration)
LTM YoY +21%; acceleration +3.8pp
LTM г/г по отчётности		100%+17% · +12% · +9%
Model assumptions
Exit multipleEV/EBITDA 4.66x (3.73x…6.82x)
No re-rating: min(current 4.7x, three-year median 5.9x). Re-rating to 6.8x on a falling rate is the bull case
Second valuation: discounted cash flow30.22 ₽ (discount 13.1%, terminal growth 4.0%)
79% of that value sits beyond the three-year horizon
Key rate by year13.2% · 9.8% · 8.1% (averaged over the 12 months to each model year end, not over the calendar year)
Cost inflation6.2% · 5.6% · 5.3%
Dividend policy19% of net profit, capped by cash flow
Year-3 EBITDA margin target37.9%
Current CPI (actual)6.3%, на 2026-09-30
Capexcapex/revenue intensity held at the base level, floored at 80% of D&A: growth may need no new plant, but wear still does
D&Agrows slower than revenue — elasticity 0.6: assets outlive the sales they carry
Interestgross debt × (that year's key rate + 1.5pp) less cash yield at 0.85 of the rate. Debt is refinanced at par; free cash after dividends accumulates and cuts net debt
Tax25% of pre-tax profit when positive; losses earn no tax credit
Working capitalneutral: FCF = EBITDA − capex − interest − tax
Governanceno flags: the dividend has not faded against profit, payouts were not suspended, no audit qualification and no manual penalty — quality multiplier 1.00
Forecast accuracy measured on history
Historical forecast checkobsmedian errorbias±20%
Revenue66%0.94x100%
EBITDA69%0.91x83%
Net profit618%0.86x67%

The model is anchored at each past reporting date with only the data available then, and its one-year-ahead forecast is compared with the actual. Rates and inflation are actuals, so this checks the operating forecast, not macro guessing.

Independent one-year estimates: eninvs Company_Forecast — 74.28 ₽; Frontier див-модель — 18.84 ₽. Ours on the same horizon — 54.70 ₽. Dropped as broken: eninvs DividendPrediction (6.333)

Checks and caveats
  • ⚠ Growth rests on a single source (momentum)
  • ⚠ The two valuations of the same cash flow differ 2.2x: exit multiple 66 vs discounted cash flow 30 — the target rests on the multiple assumption rather than on the flow; in the DCF 79% of value sits in the terminal value
  • ⚠ The share count is growing: 1000m 2.0 years ago against 1168m now — 8.0% a year, last change 2026-01-27. If that pace holds, the value of a share in year 3 is 21% below the base figure: the base holds today's count (no issue is announced) and continued dilution sits in the bear case
  • ⚠ Net debt grows for reasons beyond a cash shortfall: over 3 years it added 3.7% of revenue a year on top of cash flow and dividends (range -8.0…+11.1%) — new leases, acquisitions, revaluation. That addition is carried in the forecast; without it the model would show deleveraging where debt keeps rising
  • ⚠ Less reaches actual cash than the formula implies: over 4 reported years free cash flow came to 0.45 of 'EBITDA less capex, interest and tax'. The gap is lease principal (IFRS 16 keeps it out of EBITDA but it still has to be paid) and working capital. The forecast cash flow is scaled by this factor — otherwise debt repayment and dividends come out of cash the company never has
  • ✓ Revenue CAGR +13%
  • ✓ Year-3 margin 38% inside history 33%–39%
  • ✓ Year-3 net debt/EBITDA 0.4x
  • ✓ Three-year dividends — 11% of the current price
  • ✓ IRR +15%
  • ✓ Base is fresh: report 4 months old
  • ✓ Historical check (6 observations): median EBITDA miss 3.6 pp of margin, within ±5 pp in 50% of cases, relative error 9% at bias 0.91x, revenue 6%
  • ✓ One-year value agrees with an independent estimate: eninvs Company_Forecast (0.74x). Compared with: eninvs Company_Forecast, Frontier див-модель

A forecast, not investment advice. Related-market prices are held at today's level, so the model answers what the business earns and is worth if markets stay here — it does not predict prices.

Dividend history

Paid, trailing 12-mo: 1.30 RUB/sh · 2.8%

Pay yearDividend /sh
20261.30 ₽
20250.79 ₽
20240.18 ₽
Payments by period
PeriodLast day to buy/sh
2026 q32026-09-280.76 ₽
2026 q22026-06-020.27 ₽
2026 q12026-01-090.27 ₽
2025 q42025-10-030.25 ₽
2025 q32025-07-020.28 ₽
2025 q22025-06-040.26 ₽
2024 q42024-12-260.18 ₽

Dividends

No dividend rows found for this issuer.

Investment-community mentions

Substantive mentions last 7 days: 0, last 30 days: 3 (3 positive) across tracked channels, broker research and shows. 6 passing mentions (digests, calendars) hidden.

Sources: Telegram channels (bloggers — blue chip, broker research — green), YouTube shows via transcripts (orange). Tone (▲/▼) is an automatic assessment in the stock's context. Quotes are fragmentary; authors' views are not our recommendations.

Corporate events

21.09.26AGM / Board★ ▲ Решения общих собраний участников (акционеров)
На внеочередном собрании акционеров ПАО 'Озон Фармацевтика' принято решение о выплате дивидендов за 6 месяцев 2026 года в размере 0,49 руб. на акцию, общая сумма выплат составит 572,2 млн. руб. Дата определения лиц, имеющих право на получение дивидендов, установлена на 29 сентября 2026 года.
25.08.26Material event★ ▲ События (действия), оказывающие, по мнению эмитента, существенное влияние на стоимость или котировки его ценных бумаг
Совет директоров ПАО 'Озон Фармацевтика' рекомендовал выплатить дивиденды за I полугодие 2026 года в размере 572,2 млн руб. или 49 коп. на акцию. Общая сумма дивидендов за первое полугодие составит 887,4 млн руб. или 76 коп. на акцию, с датой определения прав на получение дивидендов 29 сентября 2026 года.
25.08.26AGM / Board★ ▲ Решения совета директоров (наблюдательного совета)
Совет директоров ПАО «Озон Фармацевтика» рекомендовал выплатить дивиденды в размере 572,2 млн. руб. по итогам работы за 6 месяцев 2026 года, что составит 0,49 руб. на акцию. Также предложена дата 29 сентября 2026 года для определения лиц, имеющих право на получение дивидендов.
09.07.26Filing★ ▼ Совершение подконтрольной эмитенту организацией существенной сделки
Компания 'Озон Фармацевтика' заключила крупную сделку на сумму 20,25 млрд. руб., что составляет 38,04% от стоимости активов, с поручительством перед 'Альфа-Банком' до 2035 года. Сделка связана с кредитным соглашением на возобновляемую кредитную линию.
26.06.26Filing★ ▲ Дата определения (фиксации) лиц, имеющих право на осуществление прав по ценным бумагам эмитента
ПАО 'Озон Фармацевтика' установило дату фиксации прав акционеров на получение дивидендов по обыкновенным акциям на 8 июля 2026 года. Регистрационный номер выпуска ценных бумаг: 1-01-10877-P, ISIN: RU000A109B25.
19.05.26Filing★ ▲ Созыв общего собрания участников (акционеров)
ПАО 'Озон Фармацевтика' проведет внеочередное общее собрание акционеров 24 июня 2026 года в форме заочного голосования. Повестка дня включает вопрос о выплате дивидендов по итогам работы за 3 месяца 2026 года. Дата окончания приема бюллетеней для голосования также 24 июня 2026 года.

Source: e-disclosure material filings over the last 180 days; ★ — flagged important by the classifier; summaries are automatic.

RU equity fund ownership

Disclosed in the top-10 of 1 of 17 funds, ≈9 млн ₽ combined.

FundManagerWeight≈PositionΔ weight m/mDisclosure
SIPO Первая – Фонд АйПиОПервая9.15%9 млн ₽—31.08.2026

Source: monthly fund portfolio disclosures (investfunds); NAV is daily. Disclosures list each fund's top-10 only, so absence does not mean no position. Weight changes mix revaluation with trading. Fund flows and betas live in the fund monitor on the RU region page.

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Ozon Pharm (OZPH) — from primary filings.

Frequently asked questions

What is Ozon Pharm (OZPH)'s P/E ratio?
Ozon Pharm (OZPH) trades at a P/E of 9.5x (price to trailing 12-month earnings).
What is Ozon Pharm (OZPH)'s EV/EBITDA?
Ozon Pharm (OZPH) trades at 5.3x EV/EBITDA.
What is Ozon Pharm (OZPH)'s P/B ratio?
Ozon Pharm (OZPH) trades at a P/B of 1.6x.
What is Ozon Pharm (OZPH)'s dividend yield?
Ozon Pharm (OZPH)'s trailing 12-month dividend yield is 2.8%.
What is Ozon Pharm (OZPH)'s return on equity (ROE)?
Ozon Pharm (OZPH)'s ROE is 18.8%.
What is Ozon Pharm (OZPH)'s market capitalization?
Ozon Pharm (OZPH)'s market cap is 54.5 bn RUB.

See also: The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map